Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs

Biochemical Pharmacology

Volumn 52, Issue 4, 1996, Pages 659-667

  Pineau, Thierry ^a,c   Robert Hudgins, W ^c   Liu, Lei ^a,b   Chen, Li Chuan ^d   Sher, Talia ^a,d   Gonzalez, Frank J ^a   Samid, Dvorit ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c CEMAGREF   (France)

^d WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Acyl CoA oxidase; Aromatic fatty acids; Clofibrate; Cytochrome P450IV; Cytostasis; Nuclear receptors; Phenylacetate; Phenylbutyrate

Indexed keywords

1 NAPHTHYLACETIC ACID; 2,4 DICHLOROPHENOXYACETIC ACID; 4 (4 CHLOROPHENYL)BUTYRIC ACID; 4 (4 IODOPHENYL)BUTYRIC ACID; 4 CHLOROPHENYLACETIC ACID; 4 PHENYLBUTYRIC ACID; ANTINEOPLASTIC AGENT; CLOFIBRATE; INDOLEACETIC ACID; PEROXISOME PROLIFERATOR; PHENYLACETIC ACID; PHENYLACETIC ACID DERIVATIVE; PHENYLACETYLGLUTAMINE; RECEPTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; FEMALE; GENE ACTIVATION; GENE EXPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; LIPID METABOLISM; LIVER; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION; TUMOR CELL;

ANIMALS; BRAIN NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS; GLIOBLASTOMA; HUMANS; LIVER; PHENYLACETATES; RABBITS; RATS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0029999619     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)00340-1     Document Type: Article

References (54)

1. Samid D, Shack S and Sherman LT, Phenylacetate: A novel nontoxic inducer of tumor cell differentiation. Cancer Res 52: 1988-1992, 1992.
2. Samid D, Shack S and Myers CE, Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by non-toxic pharmacological concentrations of phenylacetate. J Clin Invest 91: 2288-2295, 1993.
3. Samid D, Ram Z, Hudgins WR, Shack S, Liu L, Walbridge S, Oldfield EH and Myers CE, Selective activity of phenylacetate against malignant gliomas: Resemblance to fetal brain damage in phenylketonuria. Cancer Res 54: 891-895, 1994.
4. Liu L, Shack S, Stetter-Stevenson WG, Hudgins WR and Samid D, Differentiation of cultured human melanoma cells induced by the aromatic fatty acids phenylacetate and phenylbutyrate. J Invest Dermatol 103: 335-340, 1994.
5. Ram Z, Samid D, Walbridge S, Oshiro EM, Viola JJ, Tao-Cheng JH, Shack S, Thibault A, Myers CE and Oldfield EH, Growth inhibition, tumor maturation, and extended survival in experimental brain tumors in rats treated with phenylacetate. Cancer Res 54: 2923-2927, 1994.
6. ras isoprenylation and phenotypic reversion. Int J Cancer 63: 124-129, 1995.
7. Thibault A, Cooper MR, Figg WD, Venzon DJ, Sartor AO, Tompkins AC, Weinberger MS, Headless DJ, McCall N A, Samid D and Myers CE, A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res 54: 1690-1694, 1994.
8. Thibault A, Samid D, Cooper MR, Figg WD, Tompkins AC, Patronas N, Headless DJ, Kohler DR, Venzon DJ and Myers CE, Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer 75: 2932-2938, 1995.
9. Brusilow SW, Danney M, Waber J, Batshaw M, Burton B, Levitsky L, Roth K, McKeethren C and Ward J, Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis. N Engl J Med 310: 1630-1634, 1984.
10. Mendenhall CL, Rouster S, Marshall L and Weesneer RA, New therapy for portal systemic encephalopathy. Am J Gastroenterol 81: 540-543, 1986.
11. Hudgins WR, Shack S, Myers CE and Samid D, Antitumor activity of phenylacetate and derivatives: Correlation with lipophilicity and inhibition of protein prenylation. Biochem Pharmacol 50: 1273-1279, 1995.
12. Cohen BI, Raicht RF, Shefer S and Mosbach EH, Effects of clofibrate on sterol metabolism in the rat. Biochim Biophys Acta 369: 79-85, 1974.
13. Brandes R, Arad R and Bar-Tana J, Adipose conversion of cultured rat primary preadipocytes by hypolipidemic drugs. Biochim Biophys Acta 877: 314-321, 1986.
14. Chawla A and Lazar MA, Peroxisome proliferator and retinoid signalling pathways coregulate preadipocyte phenotype and survival. Proc Natl Acad Sci USA 91: 1786-1790, 1994.
15. Reddy JK and Lalwai ND, Carcinogenesis by hepatic peroxisome proliferators: Evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans. Crit Rev Toxicol 12: 1-58, 1983.
16. Issemann I and Green S, Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347: 645-650, 1990.
17. Göttlicher M, Widmark E, Li Q and Gustafsson J-A, Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci USA 89: 4653-4657, 1992.
18. Osumi T, Wen J-K and Hashimoto T, Two cis-acting regulatory sequences in the peroxisome proliferator-responsive enhancer region of rat acyl-CoA oxidase gene. Biochem Biophys Res Commun 175: 866-871, 1991.
19. Zhang B, Marcus SL, Sajjadi FG, Alvares K, Reddy JK, Subramani S, Rachubinski RA and Capone JP, Identification of a peroxisome proliferator-responsive element upstream of the gene encoding rat peroxisomal enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase. Proc Natl Acad Sci USA 89: 7541-7545, 1992.
20. Tugwood JD, Issemann I, Anderson RG, Bundell KR, McPheat WL and Green S, The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO J 11: 433-439, 1992.
21. Bardot O, Aldridge TC, Latruffe N and Green S, PPAR-RXR heterodimer activates a peroxisome proliferates response element upstream of the bifunctional enzyme gene. Biochem Biophys Res Commun 192: 37-45, 1993.
22. Marcus SL, Miyata KS, Zhang B, Subramani S, Rachubinski RA and Capone JP, Diverse peroxisome proliferator-activated receptors bind to the peroxisome proliferator-responsive elements of the rat hydratase/dehydrogenase and fatty acyl-CoA oxidase genes but differentially induce expression. Proc Natl Acad Sci USA 90: 5723-5727, 1993.
23. Muerhoff AS, Griffin KJ and Johnson EF, The peroxisome proliferator-activated receptor mediates the induction of CYP4A6, a cytochrome P450 fatty acid ω-hydroxylase, by clofibric acid. J Biol Chem 267: 19051-19053, 1992.
24. Issemann I, Prince R, Tugwood J and Green S, A role for fatty acids and liver fatty acid binding protein in peroxisome proliferation. Biochem Soc Trans 20: 824-827, 1992.
25. Simon TC, Roth KA and Gordon JI, Use of transgeneic mice to map cis-acting elements in the liver fatty acid-binding protein gene (Fabpl) that regulate its cell lineage-specific, differentiation-dependent, and spatial patterns of expression in the gut epithelium and in the liver acinus. J Biol Chem 268: 18345-18358, 1993.
26. Rodriquez JC, Gil-Gómez G, Hegardt FG and Haro D, Peroxisome proliferator-activated receptor mediates induction of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by fatty acids. J Biol Chem 269: 18767-18772, 1994.
27. Gulick T, Cresci S, Caira T, Moore D and Kelly DP, The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci USA 91: 11012-11016, 1994.
28. Castelein H, Gulick T, Declercq PE, Mannaerts GP, Moore DD and Baes MI, The peroxisome proliferator activated receptor regulates malic enzyme gene expression. J Biol Chem 269: 26754-26758, 1994.
29. Sher T, Yi H-F, McBride OW and Gonzalez FJ, cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry 32: 5598-5604, 1993.
30. Apfel R, Benbrook D, Lernhardt E, Ortiz MA, Salbert G and Pfahl MA, Novel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor subfamily. Mol Cell Biol 14: 7025-7035, 1994.
31. de Wet JR, Wood KV, DeLuca M, Helinski DR and Subramani S, Firefly luciferase gene: Structure and expression in mammalian cells. Mol Cell Biol 7: 725-737, 1987.
32. Graham FL and van der Eb AA, New technique for the assay of infectivity of human adenovirus 5 DNA. J Virol 52: 456-467, 1973.
33. German CM, Moffat LF and Howard BH, Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol 2: 1044-1051, 1982.
34. Kingston RE, Guanidinium method for total RNA preparation. In: Current Protocols in Molecular Biology (Eds. Ausubel FM, Brent R, Kingston R, Moore D, Seidman J, Smith J and Struhl K), Vol. 1, Section 4.2, pp. 4.2.1-4.2.8. Greene Publishing Associates and Wiley Interscience, New York, 1992.
35. LAω). Identification of a new cytochrome P-450 gene family. J Biol Chem 262: 801-810, 1987.
36. Gebel T, Arand M and Oesch F, Induction of the peroxisome proliferator activated receptor by fenofibrate in rat liver. FEBS Lett 309: 37-40, 1992.
37. Gearing KL, Göttlicher M, Widmark E, Banner CD, Tollet P, Strömstedt M, Rafter JJ, Berge RK and Gustafsson JA, Fatty acid activation of the peroxisome proliferator activated receptor, a member of the nuclear receptor gene superfamily. J Nutr 124 (Suppl): 1284S-1288S, 1994.
38. Denner LA, Weigel NL, Maxwell BL, Schrader WT and O'Malley BW, Regulation of progesterone receptor-mediated transcription by phosphorylation. Science 250: 1740-1743, 1990.
39. Power RF, Lydon JP, Conneely OM and O'Malley BW, Dopamine activation of an orphan of the steroid receptor super-family. Science 252: 1546-1548, 1991.
40. Keller JM, Cable S, el Bouhtoury F, Heusser S, Scotto C, Armbruster L, Ciolek E, Colin S, Schilt J and Dauça M, Peroxisome through cell differentiation and neoplasia. Biol Cell 77: 77-88, 1993.
41. Michalopoulos GK, Eckl PM, Cruise JL, Novicki DL and Jutle RL, Mechanisms of rodent liver carcinogenesis. Toxicol Ind Health 3: 119-128, 1987.
42. Butterworth BE, Smith-Oliver T, Earle L, Loury DJ, White RD, Doolittle DJ, Working PK, Cattley RC, Jirtle R, Michalopoulos G and Strom S, Use of primary cultures of human hepatocytes in toxicological studies. Cancer Res 49: 1075-1084, 1989.
43. Balaauboer BJ, van Holsteijn CWM, Bleumink R, Mennes WC, van Pelt FNAM, Yap SH, van Pelt JF, van lersel AAJ, Timmerman A and Schmid BP, The effect of beclobric acid and clofibric acid on peroxisomal β-oxidation and peroxisome proliferation in primary cultures of rat, monkey and human hepatocytes. Biochem Pharmacol 40: 521-528, 1990.
44. Thorne PC, Byers DM, Palmer FBStC and Cook HW, Clo-fibrate and other peroxisomal proliferating agents relatively specifically inhibit synthesis of ethanolamine phosphoglycerides in cultured human fibroblasts. Biochim Biophys Acta 1214: 161-170, 1994.
45. Mastuo H and Strauss JF III, Peroxisome proliferators and retinoids affect JEG-3 choriocarcinoma cell function. Endocrinology 135: 1135-1145, 1994.
46. Tontonoz P, Hu E and Spiegelman B, Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 79: 1147-1156, 1994.
47. Amri EZ, Bonino F, Ailhaud G, Abumrad N and Grimaldi P, Cloning of a protein that mediates transcriptional effects of fatty acids in preadipocytes. J Biol Chem 270: 2367-2371, 1995.
48. Oteruelo FT, PKU bodies: Characteristic inclusions in the brain in phenylketonuria. Acta Neuropathol 36: 295-305, 1976.
49. Castillo M, Martinez-Cayuela M, Zafra MF and Garcia-Peregrin E, Inhibition of chick brain cholesterogenic enzymes by phenyl and phenolic derivatives of phenylalanine. Mol Cell Biochem 105: 21-25, 1991.
50. DeClue TJ, Davis J, Schocken DM, Kangas R and Benford SA, Serum lipid concentrations in subjects with phenylketonuria and their families. Am J Dis Child 145: 1266-1268, 1991.
51. Cayen MN, Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man. Pharmacol Ther 29: 157-204, 1985.
52. Rekka E, Ayalogu EO, Lewis DFV, Gibson GG and loannides C, Induction of hepatic microsomal CYP4A activity and of peroxisomal β-oxidation by two non-steroidal anti-inflammatory drugs. Arch Toxicol 68: 73-78, 1994.
53. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Gu LJ and Wang ZY, Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72: 567-572, 1988.
54. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berge R, Fenaux P and Degos L, All-trans retinoic acid as differentiation therapy for acute promyelocytic leukemia. Blood 76: 1704-1709, 1990.